MedTrace Logo

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

NCT07588698 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-05-15

No results posted yet for this study

Summary

A Phase II, open-label, two-arm, multicenter study evaluating the combination of epcoritamab with R-CHOP chemotherapy in patients with newly diagnosed, aggressive B-cell non-Hodgkin lymphoma.

Conditions

  • Non-Hodgkin's B-cell Lymphoma
  • Lymphoma Non-Hodgkin
  • Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions

DRUG

Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP)

Given orally and intravenously (IV)

DRUG

Epcoritamab

Given subcutaneously (SC)

DRUG

Dexamethasone

Given orally

PROCEDURE

Positron Emission Tomography (PET)

Undergo imaging

PROCEDURE

Blood specimen collection

Perform Blood work

BEHAVIORAL

Questionnaires

Participants complete European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

PROCEDURE

Computerized tomography (CT)

Undergo Imaging

Sponsors & Collaborators

  • Mwanasha Merrill, MD

    lead OTHER

Principal Investigators

  • Mwanasha Merrill, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-15
Primary Completion
2028-07-31
Completion
2029-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07588698 on ClinicalTrials.gov